Formulation and Evaluation of Hyaluronic Acid-based Mucoadhesive Self Nanoemulsifying Drug Delivery System (SNEDDS) of Tamoxifen for Targeting Breast Cancer
Overview
Affiliations
The present study was intended to develop a papain grafted S-protected hyaluronic acid-lithocholic acid co-block (PAP-HA-ss-LCA) polymeric excipient as an amphiphilic muco permeating stabilizer for targeting breast cancer epithelial cells overexpressed with CD44 receptors. The mucopermeating, stabilizing and targeting capability of the PAP-HA-ss-LCA polymeric excipient was investigated by manufacturing tamoxifen (TMX) loaded self-nanoemulsifying drug delivery system (SNEDDS). TMX loaded PAP-HA-ss-LCA incorporated SNEDDS (TMX-PAP-HA-ss-LCA SNEDDS) were characterized for their surface chemistry, drug release, permeation enhancement, biocompatibility and antitumor activity. FTIR spectroscopic analysis showed successful synthesis of PAP-HA-ss-LCA polymer. X-ray diffraction (XRD) showed the amorphous form of TMX inside SNEDDS. The observed hydrodynamic diameter of TMX-PAP-HA-ss-LCA SNEDDS was 367.5 nm. Furthermore, Hyaluronic Acid-based Mucoadhesive Self Nanoemulsifying Drug Delivery System (SNEDDS) of TMX showed homogeneity in synthesis with low polydispersity and negative zeta potential due to stabilization with PAP-HA-ss-LCA polymer. The distinct spherical shape of the nanodroplets was evident by transmission electron microscopy (TEM). In vitro release kinetics indicated approximately >80% release within 48 h under sink conditions. Ex-vivo permeation study displayed 7.11-folds higher permeation of TMX by TMX-PAP-HA-ss-LCA in contrast to pure TMX. The biocompatibility study proved that SNEDDS formulation was safe and compatible against macrophages. In vitro cytotoxicity studies demonstrated that TMX-PAP-HA-ss-LCA SNEDDS could efficiently kill MCF-7 breast cancer cells as compared to the native TMX drug. Systemic toxicity studies proved the non-toxic nature of TMX-PAP-HA-ss-LCA in contrast to pure TMX. Based on these evidences, TMX-PAP-HA-ss-LCA SNEDDS formulation seems to be promising mucopermeating, augmented intracellular uptake with strong targeting potential for anti-proliferative activity.
Jang H, Kim N, Jin S Int J Mol Sci. 2025; 26(4).
PMID: 40004060 PMC: 11855893. DOI: 10.3390/ijms26041592.
Radhakrishnan A, Shanmukhan N, Samuel L Med Oncol. 2025; 42(3):67.
PMID: 39913003 DOI: 10.1007/s12032-025-02611-w.
Tan K, Chia L, Maki M, Cheah S, In L, Kumar P Naunyn Schmiedebergs Arch Pharmacol. 2025; .
PMID: 39878813 DOI: 10.1007/s00210-025-03839-z.
Basar M, Khan M, Akhtar M, Anwar F, Saleem A, Madni A Inflammopharmacology. 2025; 33(1):353-379.
PMID: 39776028 DOI: 10.1007/s10787-024-01632-7.
Advances in the delivery of anticancer drugs by nanoparticles and chitosan-based nanoparticles.
Jarmila P, Veronika M, Peter M Int J Pharm X. 2024; 8:100281.
PMID: 39297017 PMC: 11408389. DOI: 10.1016/j.ijpx.2024.100281.